{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:52:17Z","timestamp":1782993137201,"version":"3.54.5"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Myasthenia gravis \u2013 auch 2023 noch eine Herausforderung f\u00fcr Betroffene und \u00c4rzte.\n                    Aber welche Therapie ist am besten geeignet? Unsere klinisch erfahrenen Experten\n                    haben die aktuellen Leitlinien zur Diagnostik und Therapie zusammengefasst, um\n                    Betroffene optimal zu unterst\u00fctzen. Erfahren Sie, wie Sie eine schnelle und\n                    zielgerichtete Diagnostik durchf\u00fchren k\u00f6nnen und welche Behandlungsoptionen zur\n                    Verf\u00fcgung stehen, um den Verlauf der Erkrankung zu mildern.<\/jats:p>","DOI":"10.1055\/a-2238-7784","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T22:30:43Z","timestamp":1713479443000},"page":"139-156","source":"Crossref","is-referenced-by-count":1,"title":["Myasthenia gravis \u2013 Update"],"prefix":"10.1055","volume":"92","author":[{"given":"Kristina","family":"Gutschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"S Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"C Gasperi","year":"2014","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force\n                    of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of\n                    America","volume":"55","author":"A Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e01819","DOI":"10.1002\/brb3.1819","article-title":"Epidemiology of myasthenia gravis in Sweden 2006-2016","volume":"10","author":"E Westerberg","year":"2020","journal-title":"Brain Behav"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ejpn.2016.09.001","article-title":"Juvenile myasthenia gravis in Norway: A nationwide epidemiological study","volume":"21","author":"T H Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","article-title":"Epidemiology and treatment of myasthenia gravis: a retrospective study using a\n                    large insurance claims dataset in Germany","volume":"33","author":"A Mevius","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.06.2010.3091","article-title":"Bedside testing for myasthenia gravis: the ice-test","volume":"2010","author":"J Browning","year":"2010","journal-title":"BMJ Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"M Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s001150050196","article-title":"Okul\u00e4rer Myositis","volume":"68","author":"M Berkhoff","year":"1997","journal-title":"Nervenarzt"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive\n                    summary","volume":"87","author":"D B Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"L Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"G O Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"CD002828","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","volume":"2005","author":"C Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor\n                    antibodypositive refractory generalised myasthenia gravis (REGAIN): a phase 3,\n                    randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"J F Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in\n                    patients with refractory generalized myasthenia gravis","volume":"48","author":"J F Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia\n                    gravis","volume":"60","author":"S Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated\n                    with eculizumab during REGAIN and its open-label extension","volume":"96","author":"R Mantegazza","year":"2021","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis:\n                    responder analyses","volume":"8","author":"J F Howard","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis\n                    (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"J F Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised\n                    myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\n                    3 trial","volume":"20","author":"J F Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs\n                    in humans","volume":"128","author":"P Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized\n                    Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"V Bril","year":"2021","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia\n                    gravis (MycarinG): a randomised, double-blind, placebocontrolled, adaptive phase\n                    3 study","volume":"22","author":"V Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in\n                    patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX\n                    randomised trial","volume":"18","author":"G I Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized Trial of Thymectomy in Myasthenia Gravis","volume":"375","author":"G I Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2169\/internalmedicine.5934-20","article-title":"Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome\n                    with SOX-1 antibodies","volume":"60","author":"S Wada","year":"2021","journal-title":"Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1749-6632.2012.06772.x","article-title":"SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small\n                    cell lung carcinoma","volume":"1275","author":"A F Lipka","year":"2012","journal-title":"Ann N Y Acad Sci"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2238-7784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:27:12Z","timestamp":1730802432000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2238-7784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,4,18]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2238-7784","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}